Giuseppa Ruggeri
Research Subjects
Research Interests
Giuseppa Ruggeri has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Alda Ragalmuto
Oasi Research Institute-IRCCS, 94018 Troina, Italy
7 shared publications - Francesco Calì
Department Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
7 shared publications - Valentino Romano
University of Palermo
7 shared publications - Valeria Chiavetta
Laboratorio di Genetica Molecolare, UOC Laboratorio di Genetica Medica, Associazione Oasi Maria SS, IRCCS, Troina, EN, Italy
7 shared publications - Pietro Schinocca
Associazione Oasi Maria SS. (I.R.C.C.S.)
5 shared publications - Mirella Vinci
Oasi Research Institute-IRCCS, 94018 Troina, Italy
4 shared publications
Latest Publications
- 5 February 2019
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 9 (1) , 203-206
Interpreting Genetic Variants: Hints from a Family Cluster of Parkinson’s Disease
Technological innovation related to the advent and development of the Next-Generation Sequencing (NGS) has provided significant advances in the diagnosis of disorders with genetic and phenotypic variability, such as neurodegenerative diseases. Howeve
- 5 February 2019
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 9 (1) , 203-206
Interpreting Genetic Variants: Hints from a Family Cluster of Parkinson’s Disease
Technological innovation related to the advent and development of the Next-Generation Sequencing (NGS) has provided significant advances in the diagnosis of disorders with genetic and phenotypic variability, such as neurodegenerative diseases. Howeve
- 1 February 2017
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 60 (2) , 93-99
Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM™ platform
- 1 February 2017
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 60 (2) , 93-99
Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM™ platform
- 1 October 2016
- Vol. 151 (5) , 582-5
A novel splice acceptor site mutation in the ATP2A2 gene in a family with Darier disease.
- 1 October 2016
- Vol. 151 (5) , 582-5
A novel splice acceptor site mutation in the ATP2A2 gene in a family with Darier disease.
- Open Access
- 20 February 2014
- Published by Springer Nature in Journal of Genetics
- Vol. 93 (1) , 179-181
Carrier screening for spinal muscular atrophy in Italian population.
- 20 February 2014
- Published by Springer Nature in Journal of Genetics
- Vol. 93 (1) , 179-181
Open AccessCarrier screening for spinal muscular atrophy in Italian population.
- 1 January 2013
- Published by Genetics and Molecular Research in Genetics and Molecular Research
- Vol. 12 (2) , 1176-1181
Comparative multiplex dosage analysis in spinocerebellar ataxia type 2 patients
We developed a new application of comparative multiplex dosage analysis (CMDA) for evaluation of the ataxin 2 gene. Expansions of the triplet CAG can cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disease with an autosomal-dominant mode of inheritance. Molecular diagnosis of SCA2 is routinely based on the use of conventional PCR to detect the CAG expansion. However, PCR does not amplify an allele with an expansion of many triplets (>80), which is typically found in infantile and juvenile forms of SCA2, thus leading to false negatives. We propose the analysis of the ATXN2 gene by CMDA to complement existing methods currently used for the detection of large expansions of the CAG repeat. Using CMDA, the presence of any longer mutated allele in a heterozygous patient or fetus would be inferred due to dosage variation of the very frequent normal allele #22. CMDA can be completed in 1 day, at very low cost, and would be a useful tool for prenatal diagnosis and for diagnosis of presymptomatic forms of early-onset SCA2
- 1 January 2013
- Published by Genetics and Molecular Research in Genetics and Molecular Research
- Vol. 12 (2) , 1176-1181
Comparative multiplex dosage analysis in spinocerebellar ataxia type 2 patients
We developed a new application of comparative multiplex dosage analysis (CMDA) for evaluation of the ataxin 2 gene. Expansions of the triplet CAG can cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disease with an autosomal-dominant mode of inheritance. Molecular diagnosis of SCA2 is routinely based on the use of conventional PCR to detect the CAG expansion. However, PCR does not amplify an allele with an expansion of many triplets (>80), which is typically found in infantile and juvenile forms of SCA2, thus leading to false negatives. We propose the analysis of the ATXN2 gene by CMDA to complement existing methods currently used for the detection of large expansions of the CAG repeat. Using CMDA, the presence of any longer mutated allele in a heterozygous patient or fetus would be inferred due to dosage variation of the very frequent normal allele #22. CMDA can be completed in 1 day, at very low cost, and would be a useful tool for prenatal diagnosis and for diagnosis of presymptomatic forms of early-onset SCA2
- 1 January 2013
- Published by Genetics and Molecular Research in Genetics and Molecular Research
- Vol. 12 (AOP) , 2809-15
Multiplex ligation-dependent probe amplification detection of an unknown large deletion of the CREB-binding protein gene in a patient with Rubinstein-Taybi Syndrome
Rubinstein-Taybi syndrome is a rare autosomal dominant congenital disorder characterized by postnatal growth retardation, psychomotor developmental delay, skeletal anomalies, peculiar facial morphology, and tumorigenesis. Mutations in the gene encoding the cAMP response element-binding protein (CREB, also known as CREBBP or CBP) on chromosome 16p13.3 have been identified. In addition, some patients with low intelligence quotients and autistic features bear large deletions. Based on these observations, we used multiplex ligation-dependent probe amplification to search for large deletions affecting the CREBBP gene in a Rubinstein-Taybi syndrome patient. We identified a novel heterozygote deletion removing five exons (exons 17-21), encoding the histone acetyltransferase domain. We propose the use of multiplex ligation-dependent probe amplification as a fast, accurate and cheap test for detecting large deletions in the CREBBP gene in the sub-group of Rubinstein-Taybi syndrome patients with low intelligence quotients and autistic features.
- 1 January 2013
- Published by Genetics and Molecular Research in Genetics and Molecular Research
- Vol. 12 (AOP) , 2809-15
Multiplex ligation-dependent probe amplification detection of an unknown large deletion of the CREB-binding protein gene in a patient with Rubinstein-Taybi Syndrome
Rubinstein-Taybi syndrome is a rare autosomal dominant congenital disorder characterized by postnatal growth retardation, psychomotor developmental delay, skeletal anomalies, peculiar facial morphology, and tumorigenesis. Mutations in the gene encoding the cAMP response element-binding protein (CREB, also known as CREBBP or CBP) on chromosome 16p13.3 have been identified. In addition, some patients with low intelligence quotients and autistic features bear large deletions. Based on these observations, we used multiplex ligation-dependent probe amplification to search for large deletions affecting the CREBBP gene in a Rubinstein-Taybi syndrome patient. We identified a novel heterozygote deletion removing five exons (exons 17-21), encoding the histone acetyltransferase domain. We propose the use of multiplex ligation-dependent probe amplification as a fast, accurate and cheap test for detecting large deletions in the CREBBP gene in the sub-group of Rubinstein-Taybi syndrome patients with low intelligence quotients and autistic features.
- Open Access
- 1 January 2010
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 42 (2) , 81-86
Exon deletions of the phenylalanine hydroxylase gene in Italian hyperphenylalaninemics
Experimental & Molecular Medicine is an open access journal that publishes the highest quality articles in translational research and biomedical studies.
- 1 January 2010
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 42 (2) , 81-86
Open AccessExon deletions of the phenylalanine hydroxylase gene in Italian hyperphenylalaninemics
Experimental & Molecular Medicine is an open access journal that publishes the highest quality articles in translational research and biomedical studies.
- 1 January 2010
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 42 (12) , 842-8
Novel deletion of the E3A ubiquitin protein ligase gene detected by multiplex ligation-dependent probe amplification in a patient with Angelman syndrome
Angelman syndrome (AS) is a severe neurobehavioural disorder caused by failure of expression of the maternal copy of the imprinted domain located on 15q11-q13. There are different mechanisms leading to AS: maternal microdeletion, uniparental disomy, defects in a putative imprinting centre, mutations of the E3 ubiquitin protein ligase (UBE3A) gene. However, some of suspected cases of AS are still scored negativeud to all the latter mutations. Recently, it has been shown that a proportion of negative cases bear large deletions overlapping one or more exons of the UBE3A gene. These deletions are difficult to detect by conventional gene-scanning methods due to the masking effect by the non-deleted allele. In this study, we have used forud the first time multiplex ligation-dependent probe amplification (MLPA) and comparative multiplex dosage analysis (CMDA) to search for large deletions affecting the UBE3A gene. Using this approach, we identified aud novel causative deletion involving exon 8 in an affected sibling. Based on our results, we propose the use of MLPA as a fast, accurate and inexpensive test to detectud large deletions in the UBE3A gene in a small but significant percentage of AS patients
- 1 January 2010
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 42 (12) , 842-8
Novel deletion of the E3A ubiquitin protein ligase gene detected by multiplex ligation-dependent probe amplification in a patient with Angelman syndrome
Angelman syndrome (AS) is a severe neurobehavioural disorder caused by failure of expression of the maternal copy of the imprinted domain located on 15q11-q13. There are different mechanisms leading to AS: maternal microdeletion, uniparental disomy, defects in a putative imprinting centre, mutations of the E3 ubiquitin protein ligase (UBE3A) gene. However, some of suspected cases of AS are still scored negativeud to all the latter mutations. Recently, it has been shown that a proportion of negative cases bear large deletions overlapping one or more exons of the UBE3A gene. These deletions are difficult to detect by conventional gene-scanning methods due to the masking effect by the non-deleted allele. In this study, we have used forud the first time multiplex ligation-dependent probe amplification (MLPA) and comparative multiplex dosage analysis (CMDA) to search for large deletions affecting the UBE3A gene. Using this approach, we identified aud novel causative deletion involving exon 8 in an affected sibling. Based on our results, we propose the use of MLPA as a fast, accurate and inexpensive test to detectud large deletions in the UBE3A gene in a small but significant percentage of AS patients